Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

24 Sep 2007 08:00

ViaLogy PLC24 September 2007 24th September 2007Embargoed until: 0800hrs ViaLogy appoints Dr. Robert Dean as CEO ViaLogy PLC (VIY), the AIM-quoted technology company that is the leadinginnovator of network-centric, real time signal processing platforms for sensorapplications, today announces the appointment of Dr. Robert W Dean as Presidentand Chief Executive Officer (CEO) of ViaLogy LLC, its wholly-owned Americansubsidiary company based in Pasadena, California. Dr. Dean, who has served as anon-executive director on the ViaLogy PLC board since it joined AIM last year,will become an executive director on the main board. Dr. Dean moves to ViaLogy from the Science Applications InternationalCorporation (SAIC), a global systems and technical services company where he wasSenior Vice President, Corporate Market Development. Previously he has heldsenior management and board positions, concentrating on business development andstrategic planning, with such international organisations as Boeing, LockheedMartin, United Space Alliance, MacDonald Dettwiler, Electro Optic Systems, theRand Corporation and the Ball Corporation. During the President Reagan's term Dr. Dean served as Special Assistant to thePresident and was Senior Director of the National Security Council. He was alsothe senior White House executive responsible for high technology issues. Duringhis distinguished career he has held senior positions with the CentralIntelligence Agency and the US Department of State. He has received numerousawards for public service including the Grand Service Cross of the FederalRepublic of Germany, which is the highest civilian honour awarded to a foreigncitizen. "We are delighted that Bob Dean has agreed to accept the most senior managementposition with ViaLogy," said executive chairman, Terry Bond. "He has theexperience and vision that makes him the ideal person to lead us at thisexciting time in the company's development. Our technology has now beenvalidated for a number of important industrial applications. Next month,October, we will be announcing and demonstrating ViaLogy's commercial productsfor defence, oil and gas and enterprise management and business continuityapplications." Said Dr. Dean: "During the time I have served as a non-executive director ofViaLogy I have been very impressed by the potential of the company's technologyand products and the abilities of its staff. I look forward to growing the salesand marketing organisation and deploying ViaLogy products for partners andcustomers in the US and globally. "I am confident that ViaLogy will achieve the success in the market place thatits unique technology deserves." End For further information please contact: ViaLogyTerry Bond, Chairman +44 (0)1235 834734 or 07860 842756 Seymour Pierce (Broker)Mark Percy, Nominated Adviser +44 (0)20 7107 8032 Redleaf CommunicationsEmma Kane / Samantha Robbins +44 (0)20 7822 0200 About ViaLogy: Network Centric Signal Processing. ViaLogy is a leading innovator of network-centric, real-time signal processingplatforms for sensor applications. ViaLogy is currently deploying and designingcomputational systems, powered by its patented technologies, for applications inlife sciences, public safety and security, surveillance, defence andgeoseismology. Vialogy focuses on market driven problems where automation,timeliness, quality and reliability of information processing are essential.ViaLogy's core competency incorporates rapidly and accurately detecting weaksignals buried in high noise background and clutter. This technology can beemployed to solve problems involving sensor integration and information overloadchallenges involving video, telephony and control sensors, as well as forenhancement of numerous signal processing applications. For more information,visit our website at www.vialogy.com. Except for statements of historical fact, the information presented hereinconstitutes forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors which may causethe actual results, performance or achievements of the company to be materiallydifferent from any future results, performance or achievements expressed orimplied. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
15th May 20187:00 amRNSYear-end Trading Update and £2.5m Fundraising
30th Apr 20184:00 pmRNSNotice of Trading Update
29th Mar 20187:00 amRNSPremaitha to attend industry conferences in APAC
26th Mar 20187:00 amRNSUpdate on UK patent infringement claim
16th Feb 20187:00 amRNSPremaitha secures market entry into Egypt
14th Feb 201810:25 amRNSHolding(s) in Company
12th Feb 20187:00 amRNSThermo Fisher - issue of warrants
6th Feb 20187:00 amRNSPremaitha to attend key conferences in Middle East
5th Feb 20187:00 amRNSPremaitha's IONA test approved for sale in Brazil
24th Jan 20187:00 amRNSUK High Court grants right to appeal
22nd Jan 20187:00 amRNSSecured loan facility agreement with Thermo Fisher
29th Dec 20177:00 amRNSHalf Year Results
11th Dec 20177:00 amRNSPremaitha secures four further laboratories in EU
1st Dec 20179:40 amRNSPremaitha CEO Wins Outstanding Contribution Award
27th Nov 20177:00 amRNSMiddle East laboratory network expansion
23rd Nov 20177:00 amRNSPremaitha signs new partner in East Asia
21st Nov 201710:47 amRNSLitigation First Instance Judgment
30th Oct 201710:08 amRNSGrant of Share Options
24th Oct 20173:45 pmRNSResult of AGM
24th Oct 20177:00 amRNSAGM Statement
13th Oct 20177:00 amRNSMiddle East Update
29th Sep 20177:04 amRNSFinal Results
29th Sep 20177:01 amRNSNotice of AGM
21st Sep 20174:05 pmRNSHolding(s) in Company
19th Sep 20177:00 amRNSPremaitha to offer NIPT in South Africa
7th Sep 20173:10 pmRNSFurther Patent Infringement Claims
29th Aug 20177:00 amRNSApproved for Good Manufacturing Process in Brazil
18th Jul 20172:02 pmRNSHolding(s) in Company
12th Jul 20177:00 amRNSInvestment Agreement Extension with Thermo Fisher
10th Jul 20177:00 amRNSPremaitha announces two laboratory hub contracts
3rd Jul 20177:00 amRNSLitigation Update
27th Jun 20177:00 amRNSHolding(s) in Company
16th Jun 20177:00 amRNSPremaitha launches Sage NIPT solution
5th Jun 20177:00 amRNSIndia Business Update
26th May 20177:00 amRNSIONA test validation on Thermo Fisher's Ion S5
19th May 20172:30 pmRNSPremaitha welcomes NIPT recommendation in France
16th May 20177:00 amRNSYear End Trading Update
12th May 20172:15 pmRNSUpdate Re. Swiss Customer
3rd Apr 20174:48 pmRNSHolding(s) in Company
31st Mar 20174:00 pmRNSSecond tranche of warrants issued to Thermo Fisher
17th Mar 20177:15 amRNSHardman Research: Expanding global distribution
13th Mar 20177:00 amRNSPremaitha to Attend International Medical Events
2nd Mar 201711:03 amRNSCompletion of Yourgene Acquisition
27th Feb 20177:00 amRNSCompletion of Acquisition
22nd Feb 20179:37 amRNSHolding(s) in Company
20th Feb 20177:00 amRNSMiddle East Business Update
16th Feb 20175:34 pmRNSHolding(s) in Company
15th Feb 20177:00 amRNSIssue of Equity
14th Feb 20179:32 amRNSHolding(s) in Company
13th Feb 20177:00 amRNSNew partnership with European diagnostics group

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.